Ironwood Pharmaceuticals, Inc. (IRWD) Downgraded to “Sell” at ValuEngine
ValuEngine downgraded shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) from a hold rating to a sell rating in a report released on Monday morning.
Other equities analysts also recently issued reports about the company. Cowen and Company set a $20.00 price target on Ironwood Pharmaceuticals and gave the company a buy rating in a report on Friday, August 4th. BidaskClub downgraded shares of Ironwood Pharmaceuticals from a sell rating to a strong sell rating in a research report on Wednesday, August 9th. Mizuho reissued a buy rating and set a $23.00 price objective (up from $22.00) on shares of Ironwood Pharmaceuticals in a research report on Wednesday, August 2nd. Wedbush restated a neutral rating and set a $13.00 price objective on shares of Ironwood Pharmaceuticals in a research note on Friday, June 16th. Finally, J P Morgan Chase & Co restated a neutral rating and set a $19.00 price objective (down from $20.00) on shares of Ironwood Pharmaceuticals in a research note on Friday, July 21st. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $18.29.
Shares of Ironwood Pharmaceuticals (NASDAQ IRWD) opened at 16.36 on Monday. Ironwood Pharmaceuticals has a 12-month low of $12.48 and a 12-month high of $19.94. The firm’s market cap is $2.45 billion. The company has a 50 day moving average of $15.50 and a 200-day moving average of $16.92.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.05). Ironwood Pharmaceuticals had a negative return on equity of 333.83% and a negative net margin of 52.97%. The business had revenue of $65.10 million for the quarter, compared to the consensus estimate of $70.00 million. During the same period in the previous year, the firm earned ($0.16) EPS. The company’s revenue was up 19.7% on a year-over-year basis. Analysts predict that Ironwood Pharmaceuticals will post ($1.10) EPS for the current year.
Institutional investors have recently modified their holdings of the company. Strs Ohio lifted its position in Ironwood Pharmaceuticals by 132.1% during the first quarter. Strs Ohio now owns 6,500 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 3,700 shares in the last quarter. Teacher Retirement System of Texas purchased a new stake in Ironwood Pharmaceuticals in the second quarter worth about $192,000. Jane Street Group LLC purchased a new stake in Ironwood Pharmaceuticals in the first quarter worth about $194,000. Karp Capital Management Corp purchased a new stake in Ironwood Pharmaceuticals in the first quarter worth about $201,000. Finally, Raymond James Financial Services Advisors Inc. increased its position in Ironwood Pharmaceuticals by 8.0% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 12,161 shares of the biotechnology company’s stock worth $207,000 after buying an additional 898 shares in the last quarter. Institutional investors and hedge funds own 97.90% of the company’s stock.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Stock Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.